Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Scrip Asia 100 ebook

Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.


Spotlight On Earnings


Focus On Asia


Data Analysis


R&D


Roche Takes Its Time Before Joining Tricky Alzheimer’s Treatment Market

Roche Takes Its Time Before Joining Tricky Alzheimer’s Treatment Market

 

While Eisai/Biogen and Eli Lilly are focused on knocking down barriers to uptake for their anti-amyloid drugs, Roche hopes it can beat them both on safety and efficacy with its brain shuttle technology.

Pipeline Watch: Five Approvals And 15 Phase III Readouts

Pipeline Watch: Five Approvals And 15 Phase III Readouts

 
• By 

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Novo Nordisk’s Semaglutide Hits Phase III Marks In NASH

Novo Nordisk’s Semaglutide Hits Phase III Marks In NASH

 
• By 

The blockbuster GLP-1 analog demonstrated a capability for fibrosis reduction and disease resolution in the Phase III ESSENCE study. The firm plans to file for approval in 2025.

Summit Doubles Down On Lung Cancer With Ivonescimab Trial Expansion

Summit Doubles Down On Lung Cancer With Ivonescimab Trial Expansion

 

The changes expand the commercial potential of the PD-1/VEGF targeting immunotherapy's trial, but worries about delays and endpoint success have reigned in Summit's formerly skyrocketing share price.

Business


Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso

Sage Prioritizes Zurzuvae For PPD, Ends MDD Effort, Drops Zulresso

 
• By 

As Sage prioritizes Zurzuvae for postpartum depression after recent setbacks, it will stop selling Zulresso for PPD and no longer pursue Zurzuvae in major depressive disorder.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

 

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Compass Antidepression Psychedelic Still On Course Despite Delays

Compass Antidepression Psychedelic Still On Course Despite Delays

 
• By 

The company, now the most advanced clinically in the psychedelic space after the rejection of Lykos's MDMA-based post-traumatic stress disorder drug, is cutting its workforce by a third and narrowing its research focus after shifting the timeline for its late-stage depression candidate.

Fruzaqla Adds Sparkle To Takeda’s First Half

Fruzaqla Adds Sparkle To Takeda’s First Half

 
• By 

Continued growth for mainstay Entyvio and cancer newcomer Fruzaqla drove growth at Takeda in the fiscal first half, with the Japanese major brightening its outlook for the full year.

Scrip Originals


Pipeline Watch: Five Approvals And 15 Phase III Readouts

Pipeline Watch: Five Approvals And 15 Phase III Readouts

 
• By 

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Biogen Gets New Chief Medical Officer From BMS

Executives On The Move: Biogen Gets New Chief Medical Officer From BMS

 
• By 

Recent moves in the industry include changes at the top at Fennec Pharmaceuticals, plus Opthea Acquires Chief Financial Officer From Amarin, and Disc Medicine gets a new chief technical officer.

Finance Watch: Mega-Rounds Help 2024 Biopharma VC Funding Exceed 2023

Finance Watch: Mega-Rounds Help 2024 Biopharma VC Funding Exceed 2023

 
• By 

Private Company Edition: Despite a third quarter dip, venture capital investment in biopharma in 2024 is on track to beat 2023, new data confirm. VC mega-rounds of $100m or more helped boost the total, including recent financings totaling $175m for Alpha-9 and $112m for AvenCell.

Stock Watch: Biosimilar Trends Percolate Through Roche’s Q3

Stock Watch: Biosimilar Trends Percolate Through Roche’s Q3

 
• By 

Pharmaceutical company managers may view biosimilar erosion of their products’ sales in the same rose-tinted light cast by Humira’s delayed biosimilars in the US. Payers, however, may be more clear sighted.